Q2 EPS Estimates for Gossamer Bio Lifted by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a research report issued to clients and investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.15) per share for the quarter, up from their prior estimate of ($0.17). HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio's Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.17) EPS.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to analysts' expectations of $3.95 million.

Several other equities research analysts have also commented on the stock. The Goldman Sachs Group upped their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Wedbush restated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th.

Gossamer Bio Stock Performance

Shares of GOSS stock traded down $0.01 during trading hours on Monday, reaching $1.13. The company had a trading volume of 233,034 shares, compared to its average volume of 1,521,033. The firm has a market cap of $255.71 million, a PE ratio of -3.52 and a beta of 1.82. The business has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.01. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently bought and sold shares of the company. Graham Capital Management L.P. acquired a new position in Gossamer Bio in the fourth quarter valued at approximately $32,000. Virtu Financial LLC purchased a new stake in shares of Gossamer Bio during the 1st quarter worth about $38,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio in the 4th quarter valued at about $43,000. Invesco Ltd. acquired a new position in Gossamer Bio in the 1st quarter worth about $48,000. Finally, Velan Capital Investment Management LP purchased a new position in Gossamer Bio during the fourth quarter worth approximately $68,000. Hedge funds and other institutional investors own 81.23% of the company's stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.